Research programme: tRNA-based therapeutics - hC Bioscience
Latest Information Update: 17 May 2024
At a glance
- Originator hC Bioscience
- Class Antineoplastics; RNA
- Mechanism of Action Protein synthesis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer